1-aminochrysene | 23395-88-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 1-aminochrysene
• 英文别名: Chrysenamine；chrysen-1-amine
• CAS: 23395-88-2
• 化学式: C₁₈H₁₃N
• 分子量: 243.308
• InChiKey: OQENBJBTQPIZKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-acetylaminochrysene 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 10.0h， 以85%的产率得到1-aminochrysene
  参考文献：
  名称：

  Synthesis of Aminochrysenes by the Oxidative Photocyclization of Acetylaminostilbenes.

  摘要：

  在碘和空气存在下，通过乙酰氨基二苯乙烯的氧化光环化反应，然后进行水解，合成了氨基二苯乙烯衍生物。

  DOI：

  10.1248/cpb.41.1853

文献信息

• Probe for diseases with amyloid accumulation, amyloid-staining agent, remedy and preventive for diseases with amyloid accumulation and diagnostic probe and staining agent for neurofibrillary change
  申请人：Kudo Yukitsuka

  公开号：US20060018825A1

  公开（公告）日：2006-01-26

  The present invention provides compounds having high affinity for amyloid β-protein which are for the diagnosis of diseases in which amyloid β-protein accumulates, for agents for specifically staining amyloid β-protein, and for the treatment and/or prophylaxis of diseases in which amyloid β-protein accumulates. The present invention also provides probes and staining agents for neurofibrillary tangles.

  本发明提供了对淀粉样蛋白β具有高亲和力的化合物，用于诊断淀粉样蛋白β在其中积累的疾病，用于特异染色淀粉样蛋白β的试剂，以及用于治疗和/或预防淀粉样蛋白β在其中积累的疾病。本发明还提供了用于神经原纤维缠结的探针和染色试剂。
• [EN] SELECTIVE LIGANDS FOR TAU AGGREGATES<br/>[FR] LIGANDS SÉLECTIFS POUR AGRÉGATS TAU
  申请人：KARIN & STEN MORTSTEDT CBD SOLUTIONS AB

  公开号：WO2019197502A1

  公开（公告）日：2019-10-17

  The invention provides a compound of formula (I): or a pharmaceutically acceptable salt, ester, amide or carbamate thereof, or a salt of such an ester, amide or carbamate.The invention further provides uses of the compounds of formula (I) and compositions comprising compounds of formula (I), including the use of such compounds for the detection of tau deposits, and the use of such compounds and compositions as diagnostic agents in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy,or for the prevention or treatment of a disease or disorder such as Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy.

  该发明提供了化合物的结构式(I)：或其药学上可接受的盐、酯、酰胺或碳酸酯，或此类酯、酰胺或碳酸酯的盐。该发明还提供了化合物的结构式(I)的用途和包括化合物的结构式(I)的组合物，包括利用这些化合物检测tau沉积物的用途，以及将这些化合物和组合物用作诊断剂在诊断或监测疾病或障碍的进展，如阿尔茨海默病、皮质基底节变性和进行性上核性麻痹症，或用于预防或治疗疾病或障碍，如阿尔茨海默病、皮质基底节变性和进行性上核性麻痹症。
• Acetylene Derivatives And Their Use For Binding And Imaging Amyloid Plaques
  申请人：Kung Hank F.

  公开号：US20080166299A1

  公开（公告）日：2008-07-10

  The invention relates to radiolabeled compounds and their use in methods of imaging amyloid deposits, as well as to methods of their manufacture. The invention also relates to compounds for inhibiting the aggregation of amyloid proteins that form amyloid deposits, methods for delivering therapeutic agents to amyloid deposits, as well as methods of making compounds that inhibit the aggregation of amyloid proteins.

  这项发明涉及放射标记化合物及其在成像淀粉样沉积方法中的应用，以及它们的制造方法。该发明还涉及用于抑制形成淀粉样沉积的淀粉蛋白聚集的化合物，将治疗剂传递至淀粉样沉积的方法，以及制造抑制淀粉蛋白聚集的化合物的方法。
• TRICYCLIC HETEROAROMATIC COMPOUNDS AS ALPHA-SYNUCLEIN LIGANDS
  申请人：Tu Zhude

  公开号：US20130315825A1

  公开（公告）日：2013-11-28

  Derivatives of phenothiazine, phenoxazine, and phenazine compounds and their use as α-synuclein ligands are described. Also described are methods of using these compounds and their radiolabeled analogs for the detection, monitoring, and treatment of synucleinopathies, including Parkinson's disease.

  描述了吩噻嗪、苯并恶嗪和苯并嗪化合物的衍生物及其作为α-突触核蛋白配体的用途。还描述了使用这些化合物及其放射性标记类似物用于检测、监测和治疗突触核蛋白病，包括帕金森病的方法。
• Radiopharmaceuticals for diagnosing alzheimer's disease
  申请人：Schering AG

  公开号：US20020131932A1

  公开（公告）日：2002-09-19

  This invention is directed to the use of radiopharmaceuticals in diagnosing Alzheimer's disease. In particular the radiopharmaceuticals of the invention are able to pass through the blood-brain barrier and bind to the CCR1 receptor present in brain tissue of patients having Alzheimer's disease.

  这项发明涉及在诊断阿尔茨海默病中使用放射性药物。具体来说，该发明的放射性药物能够穿过血脑屏障，并结合到患有阿尔茨海默病的患者脑组织中存在的CCR1受体上。